108 posters,  9 topics,  397 authors,  84 institutions

ePostersLive® by SciGen® Technologies S.A. All rights reserved.

Poster 14
Percutaneous Microwave Ablation of Localized T1b RCC: Local Tumor Control, Safety and Procedural Considerations

Primary tabs


No votes yet


512 reads

Percutaneous microwave ablation of localized T1b RCC: Local tumor control, safety and procedural considerations

Michael P. Hartung1, E. Jason Abel2, Brett A. Johnson2, Sara L. Best2, Timothy J. Ziemlewicz1, Meghan G. Lubner1, J. Louis Hinshaw1, Fred T. Lee Jr.1, Shane A. Wells1

1Deptartment of Radiology, School of Medicine & Public Health; UW-Madison, Madison, WI; 2Department of Urology, School of Medicine & Public Health

•Percutaneous thermal ablation is an established treatment  for renal cell carcinoma (RCC)
•Thermal ablation is a recommended alternative to surgery for T1a RCC (≤4cm)
•High-powered microwave (MW) ablation is promising modality for T1a RCC
•Thermal ablation is an option for T1b RCC (4.1-7cm) in patients who are unfit for surgery
•However, very little data exists regarding the durable oncologic efficacy of MW ablation of T1b RCC
•Our purpose is to evaluate the effect of tumor size and complexity on early and midterm treatment efficacy and rate of complications for 33 consecutive biopsy-proven T1b RCC treated with MW ablation


•32 consecutive patients with 33 biopsy-proven T1b RCC treated with percutaneous MW ablation between 2012 and 2017
•Curative intent
•No staged ablations
•Patient and procedural data evaluated:
•Maximum tumor diameter
•RENAL nephrometry score
•Stratifies renal mass complexity based on cross-sectional imaging
•Charlson Comorbidity Index (CCI)
•Predicts 10-year survival
•Body mass index (BMI) 
•Procedural technique
•Technical success
•Primary and secondary effectiveness
•Post-procedural data evaluated:
•Local and distant tumor progression
•Delayed complications

MW ablation of localized T1b renal cell carcinoma (4.1-7cm) offers:

•Favorable safety profile
•Despite an obese and highly comorbid cohort  
•Promising early and mid-term oncologic control
•91% primary efficacy
•100% secondary efficacy
•3% local tumor progression
•successfully re-ablated
Enter Poster ID (e.gGoNextPreviousCurrent